Priming increases the anti-tumor effect and therapeutic window of 177Lu-octreotate in nude mice bearing human small intestine neuroendocrine tumor GOT1 | springermedicine.com

Springer Medicine

Top

EJNMMI Research

Published in:

Open Access 01-12-2017 | Original research

Priming increases the anti-tumor effect and therapeutic window of ¹⁷⁷Lu-octreotate in nude mice bearing human small intestine neuroendocrine tumor GOT1

Authors: Johanna Dalmo, Johan Spetz, Mikael Montelius, Britta Langen, Yvonne Arvidsson, Henrik Johansson, Toshima Z. Parris, Khalil Helou, Bo Wängberg, Ola Nilsson, Maria Ljungberg, Eva Forssell-Aronsson

Published in: EJNMMI Research | Issue 1/2017

Login to get access

Abstract

Background

¹⁷⁷Lu-[DOTA⁰, Tyr³]-octreotate (¹⁷⁷Lu-octreotate) is used for treatment of patients with somatostatin receptor (SSTR) expressing neuroendocrine tumors. However, complete tumor remission is rarely seen, and optimization of treatment protocols is needed. In vitro studies have shown that irradiation can up-regulate the expression of SSTR1, 2 and 5, and increase ¹⁷⁷Lu-octreotate uptake.

The aim of the present study was to examine the anti-tumor effect of a ¹⁷⁷Lu-octreotate priming dose followed 24 h later by a second injection of ¹⁷⁷Lu-octreotate compared to a single administration of ¹⁷⁷Lu-octreotate, performed on the human small intestine neuroendocrine tumor cell line, GOT1, transplanted to nude mice.

Results

Priming resulted in a 1.9 times higher mean absorbed dose to the tumor tissue per administered activity, together with a reduced mean absorbed dose for kidneys. Priming gave the best overall anti-tumor effects. Magnetic resonance imaging showed no statistically significant difference in tumor response between treatment with and without priming. Gene expression analysis demonstrated effects on cell cycle regulation. Biological processes associated with apoptotic cell death were highly affected in the biodistribution and dosimetry study, via differential regulation of, e.g., APOE, BAX, CDKN1A, and GADD45A.

Conclusions

Priming had the best overall anti-tumor effects and also resulted in an increased therapeutic window. Results indicate that potential biomarkers for tumor regrowth may be found in the p53 or JNK signaling pathways. Priming administration is an interesting optimization strategy for ¹⁷⁷Lu-octreotate therapy of neuroendocrine tumors, and further studies should be performed to determine the mechanisms responsible for the reported effects.

Available only for authorised users

1.

Kolby L, Bernhardt P, Johanson V, Schmitt A, Ahlman H, Forssell-Aronsson E, et al. Successful receptor-mediated radiation therapy of xenografted human midgut carcinoid tumour. Br J Cancer. 2005;93(10):1144–51.CrossRefPubMedPubMedCentral

2.

Stolz B, Weckbecker G, Smith-Jones PM, Albert R, Raulf F, Bruns C. The somatostatin receptor-targeted radiotherapeutic [⁹⁰Y-DOTA-DPhe¹, Tyr³]octreotide (⁹⁰Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Eur J Nucl Med. 1998;25(7):668–74.CrossRefPubMed

3.

de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, et al. [177Lu-DOTA0, Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer. 2001;92(5):628–33.CrossRefPubMed

4.

Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27(3):273–82.CrossRefPubMed

5.

Schmitt A, Bernhardt P, Nilsson O, Ahlman H, Kölby L, Maecke HR, et al. Radiation therapy of small cell lung cancer with 177Lu-DOTA-Tyr3-octreotate in an animal model. J Nucl Med. 2004;45(9):1542–8.PubMed

6.

Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124–30.CrossRefPubMed

7.

Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38(12):2125–35.CrossRefPubMed

8.

Forssell-Aronsson E, Spetz J, Ahlman H. Radionuclide therapy via SSTR: future aspects from experimental animal studies. Neuroendocrinology. 2013;97(1):86–98.CrossRefPubMed

9.

Nilsson O, Arvidsson Y, Johanson V, Forssell-Aronsson E, Ahlman H. New medical strategies for midgut carcinoids. Anti Cancer Agents Med Chem. 2010;10(3):250–69.CrossRef

10.

Oddstig J, Bernhardt P, Nilsson O, Ahlman H, Forssell-Aronsson E. Radiation-induced up-regulation of somatostatin receptor expression in small cell lung cancer in vitro. Nucl Med Biol. 2006;33(7):841–6.CrossRefPubMed

11.

Oddstig J, Bernhardt P, Nilsson O, Ahlman H, Forssell-Aronsson E. Radiation induces up-regulation of somatostatin receptors 1, 2, and 5 in small cell lung cancer in vitro also at low absorbed doses. Cancer Biother Radiopharm. 2011;26(6):759–65.CrossRefPubMed

12.

Oddstig J, Bernhardt P, Lizana H, Nilsson O, Ahlman H, Kolby L, et al. Inhomogeneous activity distribution of ¹⁷⁷Lu-DOTA⁰-Tyr³-octreotate and effects on somatostatin receptor expression in human carcinoid GOT1 tumors in nude mice. Tumour Biol. 2012;33(1):229–39.CrossRefPubMed

13.

Bernhardt P, Oddstig J, Kolby L, Nilsson O, Ahlman H, Forssell-Aronsson E. Effects of treatment with (177)Lu-DOTA-Tyr(3)-octreotate on uptake of subsequent injection in carcinoid-bearing nude mice. Cancer Biother Radiopharm. 2007;22(5):644–53.CrossRefPubMed

14.

Larsson M, Bernhardt P, Svensson JB, Wängberg B, Ahlman H, Forssell-Aronsson E. Estimation of absorbed dose to the kidneys in patients after treatment with 177 Lu-octreotate: comparison between methods based on planar scintigraphy. EJNMMI Res. 2012;2(1):1.CrossRef

15.

Kolby L, Bernhardt P, Ahlman H, Wangberg B, Johanson V, Wigander A, et al. A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transporter-mediated radionuclide uptake. Am J Pathol. 2001;158(2):745–55.CrossRefPubMedPubMedCentral

16.

Spetz J, Dalmo J, Nilsson O, Wängberg B, Ahlman H, Forssell-Aronsson E. Specific binding and uptake of 131I-MIBG and 111In-octreotide in metastatic paraganglioma–tools for choice of radionuclide therapy. Horm Metab Res. 2012;44(05):400–4.CrossRefPubMed

17.

Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry—standardization of nomenclature. J Nucl Med. 2009;50(3):477–84.CrossRefPubMed

18.

Icrp. Annex A. Radionuclides of the ICRP-07 collection. Ann ICRP. 2008;38(3):35–96.CrossRef

19.

Eckerman K, Endo A. ICRP publication 107. Nuclear decay data for dosimetric calculations. Ann ICRP. 2007;38(3):7–96.

20.

Uusijarvi H, Bernhardt P, Forssell-Aronsson E. Translation of dosimetric results of preclinical radionuclide therapy to clinical situations: influence of photon irradiation. Cancer Biother Radiopharm. 2007;22(2):268–74.CrossRefPubMed

21.

Hennig J, Nauerth A, Friedburg H. RARE imaging: a fast imaging method for clinical MR. Magn Reson Med. 1986;3(6):823–33.CrossRefPubMed

22.

Montelius M, Ljungberg M, Horn M, Forssell-Aronsson E. Tumour size measurement in a mouse model using high resolution MRI. BMC Med Imaging. 2012;12:12.CrossRefPubMedPubMedCentral

23.

Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. Nat Genet. 2000;25(1):25–9.CrossRefPubMedPubMedCentral

24.

Parris TZ, Danielsson A, Nemes S, Kovacs A, Delle U, Fallenius G, et al. Clinical implications of gene dosage and gene expression patterns in diploid breast carcinoma. Clin Cancer Res. 2010;16(15):3860–74.CrossRefPubMed

25.

Eriksson D, Stigbrand T. Radiation-induced cell death mechanisms. Tumour Biol. 2010;31(4):363–72.CrossRefPubMed

26.

Orth M, Lauber K, Niyazi M, Friedl AA, Li M, Maihofer C, et al. Current concepts in clinical radiation oncology. Radiat Environ Biophys. 2014;53(1):1–29.CrossRefPubMed

27.

Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98(7):1521–30.CrossRefPubMed

28.

Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol. 1995;57:289–300.

29.

Muller C, Forrer F, Bernard BF, Melis M, Konijnenberg M, Krenning EP, et al. Diagnostic versus therapeutic doses of [¹⁷⁷Lu-DOTA⁰-Tyr³]-octreotate: uptake and dosimetry in somatostatin receptor-positive tumors and normal organs. Cancer Biother Radiopharm. 2007;22(1):151–9.CrossRefPubMed

30.

Fokas E, Hanze J, Kamlah F, Eul BG, Lang N, Keil B, et al. Irradiation-dependent effects on tumor perfusion and endogenous and exogenous hypoxia markers in an A549 xenograft model. Int J Radiat Oncol Biol Phys. 2010;77(5):1500–8.CrossRefPubMed

31.

Bussink J, Kaanders JH, Strik AM, Vojnovic B, van Der Kogel AJ. Optical sensor-based oxygen tension measurements correspond with hypoxia marker binding in three human tumor xenograft lines. Radiat Res. 2000;154(5):547–55.CrossRefPubMed

32.

Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0, Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2009;36(7):1138–46.CrossRefPubMedPubMedCentral

33.

Schmitt A, Bernhardt P, Nilsson O, Ahlman H, Kolby L, Schmitt J, et al. Biodistribution and dosimetry of 177Lu-labeled [DOTA0, Tyr3]octreotate in male nude mice with human small cell lung cancer. Cancer Biother Radiopharm. 2003;18(4):593–9.CrossRefPubMed

34.

Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev. 2003;24(1):28–47.CrossRefPubMed

35.

Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [¹¹¹In-DTPA-D-Phe¹]- and [¹²³I-Tyr³]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20(8):716–31.CrossRefPubMed

36.

Waser B, Tamma ML, Cescato R, Maecke HR, Reubi JC. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J Nucl Med. 2009;50(6):936–41.CrossRefPubMed

37.

Froidevaux S, Hintermann E, Török M, Mäcke HR, Beglinger C, Eberle AN. Differential regulation of somatostatin receptor type 2 (sst 2) expression in AR4-2J tumor cells implanted into mice during octreotide treatment. Cancer Res. 1999;59(15):3652–7.PubMed

38.

Huang MQ, Pickup S, Nelson DS, Qiao H, Xu HN, Li LZ, et al. Monitoring response to chemotherapy of non-Hodgkin’s lymphoma xenografts by T(2)-weighted and diffusion-weighted MRI. NMR Biomed. 2008;21(10):1021–9.CrossRefPubMed

39.

Gambarota G, Veltien A, van Laarhoven H, Philippens M, Jonker A, Mook OR, et al. Measurements of T1 and T2 relaxation times of colon cancer metastases in rat liver at 7 T. Magma. 2004;17(3-6):281–7.CrossRefPubMed

40.

Rudqvist N, Spetz J, Schuler E, Langen B, Parris TZ, Helou K, et al. Gene expression signature in mouse thyroid tissue after (131)I and (211)At exposure. EJNMMI Res. 2015;5(1):59.CrossRefPubMedPubMedCentral

41.

Schuler E, Rudqvist N, Parris TZ, Langen B, Spetz J, Helou K, et al. Time- and dose rate-related effects of internal (177)Lu exposure on gene expression in mouse kidney tissue. Nucl Med Biol. 2014;41(10):825–32.CrossRefPubMed

42.

Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88(3):323–31.CrossRefPubMed

43.

Pernot E, Hall J, Baatout S, Benotmane MA, Blanchardon E, Bouffler S, et al. Ionizing radiation biomarkers for potential use in epidemiological studies. Mutat Res. 2012;751(2):258–86.CrossRefPubMed

44.

Wilhelm M, Xu Z, Kukekov NV, Gire S, Greene LA. Proapoptotic Nix activates the JNK pathway by interacting with POSH and mediates death in a Parkinson disease model. J Biol Chem. 2007;282(2):1288–95.CrossRefPubMed

45.

Wang B, Xiao JL, Ling YH, Meng XJ, Wu B, Yang XY, et al. BNIP3 upregulation by ERK and JNK mediates cadmium-induced necrosis in neuronal cells. Toxicol Sci. 2014;140(2):393–402.CrossRefPubMed

46.

Plachta N, Annaheim C, Bissiere S, Lin S, Ruegg M, Hoving S, et al. Identification of a lectin causing the degeneration of neuronal processes using engineered embryonic stem cells. Nat Neurosci. 2007;10(6):712–9.CrossRefPubMed

47.

Subramanian SL, Hull RL, Zraika S, Aston-Mourney K, Udayasankar J, Kahn SE. cJUN N-terminal kinase (JNK) activation mediates islet amyloid-induced beta cell apoptosis in cultured human islet amyloid polypeptide transgenic mouse islets. Diabetologia. 2012;55(1):166–74.CrossRefPubMed

48.

Liu L, Aboud O, Jones RA, Mrak RE, Griffin WS, Barger SW. Apolipoprotein E expression is elevated by interleukin 1 and other interleukin 1-induced factors. J Neuroinflammation. 2011;8:175.CrossRefPubMedPubMedCentral

49.

Kennedy D, Jager R, Mosser DD, Samali A. Regulation of apoptosis by heat shock proteins. IUBMB Life. 2014;66(5):327–38.CrossRefPubMed

50.

Wang X, Mader MM, Toth JE, Yu X, Jin N, Campbell RM, et al. Complete inhibition of anisomycin and UV radiation but not cytokine induced JNK and p38 activation by an aryl-substituted dihydropyrrolopyrazole quinoline and mixed lineage kinase 7 small interfering RNA. J Biol Chem. 2005;280(19):19298–305.CrossRefPubMed

Title: Priming increases the anti-tumor effect and therapeutic window of 177Lu-octreotate in nude mice bearing human small intestine neuroendocrine tumor GOT1
Authors: Johanna Dalmo
Johan Spetz
Mikael Montelius
Britta Langen
Yvonne Arvidsson
Henrik Johansson
Toshima Z. Parris
Khalil Helou
Bo Wängberg
Ola Nilsson
Maria Ljungberg
Eva Forssell-Aronsson
Publication date: 01-12-2017
Publisher: Springer Berlin Heidelberg
Published in: EJNMMI Research / Issue 1/2017
Electronic ISSN: 2191-219X
DOI: https://doi.org/10.1186/s13550-016-0247-y

Home
Congress Coverage
Clinical Collections
- Advances in Alzheimer’s
About Springer Medicine
Key Specialties